Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
Adriamycin-based chemotherapy is commonly used for malignant soft tissue sarcoma including myxoid liposarcoma. However, in the case of unavailability or failure of the adriamycin-based regimen, trabectedin or eribulin can produce a good antitumor effect for myxoid liposarcoma. We relate the experien...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Orthopedics |
| Online Access: | http://dx.doi.org/10.1155/2020/8873185 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560048163782656 |
|---|---|
| author | Hironari Tamiya Hideaki Sabe Katsunari Yamashita Yoshinori Imura Toru Wakamatsu Satoshi Takenaka |
| author_facet | Hironari Tamiya Hideaki Sabe Katsunari Yamashita Yoshinori Imura Toru Wakamatsu Satoshi Takenaka |
| author_sort | Hironari Tamiya |
| collection | DOAJ |
| description | Adriamycin-based chemotherapy is commonly used for malignant soft tissue sarcoma including myxoid liposarcoma. However, in the case of unavailability or failure of the adriamycin-based regimen, trabectedin or eribulin can produce a good antitumor effect for myxoid liposarcoma. We relate the experience of a 64-year-old female with myxoid liposarcoma, who noticed a nodule on her left thigh and visited our institute. At initial presentation, the tumor was 18.7 cm in diameter, and the magnetic resonance imaging (MRI) showed a malignant lipomatous tumor with a myxoid component. We recommended that she undergo treatment; however, she refused. Three years later, the tumor had grown larger, so she finally decided to undergo treatment. A needle biopsy revealed a myxoid liposarcoma. The tumor massively involved the neurovascular structures; we thus determined that hip disarticulation was inevitable. Two years later, metastases in the right thigh, left lung, right ileum, and abdominal space were pointed out and chemotherapy was initiated. Adriamycin was unusable due to cardiac dysfunction, so trabectedin was administered; however, the tumors progressed. Eribulin was subsequently started and has been considerably effective for more than 2 years without severe adverse effects. In conclusion, we experienced a case showing the remarkable and long-lasting effect of eribulin against trabectedin-resistant myxoid liposarcoma. |
| format | Article |
| id | doaj-art-8b5262487b1a4bbf84fd0c7ae4b85bac |
| institution | Kabale University |
| issn | 2090-6749 2090-6757 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Orthopedics |
| spelling | doaj-art-8b5262487b1a4bbf84fd0c7ae4b85bac2025-02-03T01:28:33ZengWileyCase Reports in Orthopedics2090-67492090-67572020-01-01202010.1155/2020/88731858873185Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid LiposarcomaHironari Tamiya0Hideaki Sabe1Katsunari Yamashita2Yoshinori Imura3Toru Wakamatsu4Satoshi Takenaka5Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanAdriamycin-based chemotherapy is commonly used for malignant soft tissue sarcoma including myxoid liposarcoma. However, in the case of unavailability or failure of the adriamycin-based regimen, trabectedin or eribulin can produce a good antitumor effect for myxoid liposarcoma. We relate the experience of a 64-year-old female with myxoid liposarcoma, who noticed a nodule on her left thigh and visited our institute. At initial presentation, the tumor was 18.7 cm in diameter, and the magnetic resonance imaging (MRI) showed a malignant lipomatous tumor with a myxoid component. We recommended that she undergo treatment; however, she refused. Three years later, the tumor had grown larger, so she finally decided to undergo treatment. A needle biopsy revealed a myxoid liposarcoma. The tumor massively involved the neurovascular structures; we thus determined that hip disarticulation was inevitable. Two years later, metastases in the right thigh, left lung, right ileum, and abdominal space were pointed out and chemotherapy was initiated. Adriamycin was unusable due to cardiac dysfunction, so trabectedin was administered; however, the tumors progressed. Eribulin was subsequently started and has been considerably effective for more than 2 years without severe adverse effects. In conclusion, we experienced a case showing the remarkable and long-lasting effect of eribulin against trabectedin-resistant myxoid liposarcoma.http://dx.doi.org/10.1155/2020/8873185 |
| spellingShingle | Hironari Tamiya Hideaki Sabe Katsunari Yamashita Yoshinori Imura Toru Wakamatsu Satoshi Takenaka Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma Case Reports in Orthopedics |
| title | Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma |
| title_full | Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma |
| title_fullStr | Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma |
| title_full_unstemmed | Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma |
| title_short | Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma |
| title_sort | eribulin provides a remarkable effect in trabectedin resistant myxoid liposarcoma |
| url | http://dx.doi.org/10.1155/2020/8873185 |
| work_keys_str_mv | AT hironaritamiya eribulinprovidesaremarkableeffectintrabectedinresistantmyxoidliposarcoma AT hideakisabe eribulinprovidesaremarkableeffectintrabectedinresistantmyxoidliposarcoma AT katsunariyamashita eribulinprovidesaremarkableeffectintrabectedinresistantmyxoidliposarcoma AT yoshinoriimura eribulinprovidesaremarkableeffectintrabectedinresistantmyxoidliposarcoma AT toruwakamatsu eribulinprovidesaremarkableeffectintrabectedinresistantmyxoidliposarcoma AT satoshitakenaka eribulinprovidesaremarkableeffectintrabectedinresistantmyxoidliposarcoma |